Iminotiadiazina dioxide compounds as inhibitors of Enzyme Dissociation of beta site app (BACE), compositions, and their use

摘要

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including the compounds of Formula (I): and includes their stereoisomers, and the pharmaceutically acceptable salts of such compounds, stereoisomers. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to make them advantageous as Beta site APP Dissociation Enzyme (BACE) inhibitors and / or for treatment and3. Prevention of various diseases related to acetamide production ("a"). Pharmaceutical compounds containing one or more of these compounds (used alone and in combination with one or more other active agents) are also describedAnd procedures for the production and use of beta HCH in the treatment of pathological processes related to beta acylamin,It includes Alzheimer's disease, Parkinson's disease, Down's syndrome, Iberian ameluyd vascular disease, cerebrovascular disease, hereditary cerebral hemorrhage, mild cognitive impairment (MCI).Glaucoma, amiloride dosage, type 2 diabetes, amiloric disease related to diabetes, scrapie, bovine spongiform encephalitis, creutzfeld Jakob disease and traumatic brain injury.